Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran
Crossref DOI link: https://doi.org/10.14196/mjiri.31.39
Published Online: 2017-12-30
Update policy: https://doi.org/10.14196/mjiri.crossmark_policy
Ebadi Fard Azar, Amir Ali
Rezapour, Aziz
Alipour, Vahid
Sarabi-Asiabar, Ali
Gray, Serajaddin
Mobinizadeh, Mohammadreza
Yousefvand, Mani
Arabloo, Jalal